Cover Image
市場調查報告書

AVP-825(偏頭痛)- 預測與市場分析

AVP-825 (Migraine) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 301157
出版日期 內容資訊 英文 56 Pages
訂單完成後即時交付
價格
Back to Top
AVP-825(偏頭痛)- 預測與市場分析 AVP-825 (Migraine) - Forecast and Market Analysis to 2023
出版日期: 2014年03月31日 內容資訊: 英文 56 Pages
簡介

偏頭痛的治療藥市場上的學名藥已呈飽和狀態,上市剩下來的品牌藥,除了慢性偏頭痛治療藥Botox之外,預測在今後數年將失去壟斷性。偏頭痛的治療藥市場預測到2023年將擴大到37億美金的規模,並以CAGR3.6%的速度成長。

本報告提供偏頭痛治療藥──AVP-825之調查分析,提供疾病概要和治療指南,競爭情形,產品資訊,銷售額預測等,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
    • 預測
  • 症狀
    • 徵兆
    • 前驅症狀
    • 頭痛
    • 後發症狀

第4章 疾病的管理

  • 治療概要
    • 急性偏頭痛
    • 預防性偏頭痛

第5章 競爭評估

  • 概要
  • 策略性競爭企業的評估

第6章 機會及未滿足需求

  • 概要
  • 未滿足需求的差距分析

第7章 開發平台評估

  • 概要
  • 臨床開發中的潛力藥物

第8章 AVP-825

  • 概要
  • 功效
  • 安全性
  • 給藥·處方
  • 潛在的臨床性地位
  • 潛在的商業性地位
  • 價格與回本
  • SWOT分析
  • 預測

第9章 附錄

圖表

目錄
Product Code: GDHC382DFR

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

OptiNose, a private medical device company, is developing a low-dose sumatriptan powder formulation to be delivered intranasally using its breath-powered nasal delivery technology. The technology has been designed to deliver drugs efficiently and reliably to the targeted, hard-to-reach areas. Avanir will hold responsibilities for regulatory, manufacturing, supply-chain and commercialization activities for AVP-825.

Scope

  • Overview of Migraine, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on AVP-825 including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for AVP-825 for the US from 2012 to 2023.
  • Sales information covered for the US.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Migraine
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of AVP-825 performance
  • Obtain sales forecast for AVP-825 from 2012-2023 in the US.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
  • 3.2. Symptoms
    • 3.2.1. Premonitory Phase
    • 3.2.2. Aura Phase
    • 3.2.3. Headache Phase
    • 3.2.4. Postdrome Phase

4. Disease Management

  • 4.1. Treatment Overview
    • 4.1.1. Acute Migraine Treatment
    • 4.1.2. Preventive Migraine Treatment

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Opportunity and Unmet Need

  • 6.1. Overview
    • 6.1.1. A Lack of Acute Therapies for Patients with or at Risk of Cardiovascular Disorders
    • 6.1.2. Lack of Acute Therapies for Patients Unresponsive to Triptan Medication
    • 6.1.3. Lack of Diagnostic Tools Causes Misdiagnosis
    • 6.1.4. Physician Education
    • 6.1.5. Effective and Well-Tolerated Prophylactic Therapies
  • 6.2. Unmet Needs Gap Analysis
    • 6.2.1. Acute Therapies for Patients with or at Risk of Cardiovascular Disorders and for Patients Unresponsive to Triptan Medication
    • 6.2.2. Effective and Well-Tolerated (Migraine-Specific) Preventive Therapies
    • 6.2.3. Physician Education
    • 6.2.4. Diagnostic Tools

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising drugs in clinical development

8. AVP-825

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical Positioning
  • 8.6. Potential Commercial Positioning
  • 8.7. Pricing and Reimbursement
  • 8.8. SWOT Analysis
  • 8.9. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Migraine Patients
    • 9.4.2. Percent Drug-treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Generic Erosion
    • 9.4.5. Pricing of Pipeline agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. Survey of Prescribing Physicians
  • 9.7. About the Authors
    • 9.7.1. Author
    • 9.7.2. Reviewer
    • 9.7.3. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Classification of Migraine Subtypes
  • Table 2: Diagnostic Criteria for Migraine with Aura
  • Table 3: Diagnostic Criteria for Migraine without Aura
  • Table 4: Treatment Guidelines for Migraine
  • Table 5: Most Prescribed Drugs for Migraine by Class in the Major Markets, 2013
  • Table 6: Overall Unmet Needs - Current Level of Attainment
  • Table 7: Clinical Unmet Needs - Gap Analysis, 2013
  • Table 8: Migraine - Promising Late-Stage Pipeline, 2013
  • Table 9: Comparison of Therapeutic Classes in Development for Migraine, 2013
  • Table 10: Product Profile - AVP-825
  • Table 11: AVP-825 SWOT Analysis, 2013
  • Table 12: Global Sales Forecasts ($m) for AVP-825, 2012-2023
  • Table 13: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Migraine Treatment Algorithm in the 7MM
  • Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Migraine, 2012-2023
Back to Top